We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Potential therapeutic efficiency of pan-ERBB inhibitors for canine glioma.
- Authors
Noguchi, Shunsuke; Yasumura, Moeka
- Abstract
Canine glioma is one of the most common brain tumors with poor prognosis, making effective chemotherapy highly desirable. Previous studies have suggested that ERBB4, a signaling molecule involving one of the epidermal growth factor receptors (EGFR), may be a promising therapeutic target. In this study, the anti-tumor effects of pan-ERBB inhibitors, which can inhibit the phosphorylation of ERBB4, were evaluated both in vitro and in vivo using a canine glioblastoma cell line. The results demonstrated that both afatinib and dacomitinib effectively reduced the expression of phosphorylated ERBB4, and significantly decreased the number of viable cells, ultimately prolonging the survival time of orthotopically xenografted mice. Further downstream of ERBB4, afatinib was found to suppress the expression of phosphorylated Akt and phosphorylated Extracellular signal-related kinases1 and 2 (ERK1/2) and induced apoptotic cell death. Thus, pan-ERBB inhibition is a promising therapeutic strategy for the treatment of canine gliomas.
- Publication
Veterinary Research Communications, 2023, Vol 47, Issue 4, p2207
- ISSN
0165-7380
- Publication type
Article
- DOI
10.1007/s11259-023-10117-x